Science with a new approach
We develop ILB®, a novel molecule that has demonstrated unique properties in stimulating the body’s own repair mechanisms in e.g. neurodegenerative conditions.
ILB’s mechanism of action may either reduce the triggers that lead to cell death or prevent further pathology even if triggers are present. By addressing the underlying processes of disease, ILB could significantly improve outcomes for people suffering from otherwise untreatable progressive and disabling conditions.
“We are very excited about the clinical potential for ILB,
which may prove to be a game-changing treatment for
many devastating diseases.”
Professor Ann LoganScientific Director,
Neuregenix Ltd.
Game changing scientific innovation
We combine independent expertise in drug development with extensive business and scientific experience to navigate the complex pathway from lab to commercialisation. Our desire to drive scientific innovation is founded on a patient-centric vision, a clear business strategy, comprehensive product protection, and strong development partnerships. Our open information policy keeps our partners informed of our achievements while respecting the need for confidentiality.
Contact us
Contact TikoMed AB for more information on the company, its offerings, and partnering intentions.
News and events
TikoMed appoints Dr Björn Pilström as new Chief Executive, Henrik Otendal returns to CFO role.
30 september 2025
TikoMed’s Board of Directors has appointed Dr Björn Pilström as Chief Executive Officer of TikoMed. Dr Pilström has an MD…
Oslo University Hospital announces the startup of a multicentre randomized phase 2 trial of ILB® in ALS, commencing early 2026. The study will compare ILB® to Riluzole, the current standard of care, and will include 116 patients over a 12-month study period.
15 augusti 2025
Senior consultant neurologist Dr Angelina Hatlø Maniaol is coordinating investigator for the study, which will consist of a 6-month double-blind…
TikoMed elects a new Board of Directors – Annika Kollén and Anders Svensson join the board
10 juli 2025
At the Annual General Meeting on 30 June 2025, TikoMed elected a new board of directors for the period until…